This is a triple-peptide blend aimed at cognitive and mood-related research endpoints, combining
three peptides with distinct neuro mechanisms. Each has its own monograph; this entry covers why
they are combined and what that does and doesn't rest on.
Composition.
A roughly 30mg total-peptide vial blend of PE-22-28 (a TREK-1 potassium-channel inhibitor studied in
antidepressant models), Selank (an anxiolytic peptide derived from the immunopeptide tuftsin),
and Semax (a nootropic peptide derived from an ACTH(4-10) fragment). See each component
monograph for its pharmacology.
Combination rationale.
The rationale is complementary CNS mechanisms: PE-22-28's ion-channel action (a mood/antidepressant
research target), Selank's anxiolytic profile, and Semax's reported nootropic/neurotrophic effects.
Selank and Semax are frequently studied and used together in the Russian-language nootropic
literature; adding PE-22-28 is a more recent, less-characterised extension.
What the research shows.
Each component has its own (mostly preclinical, largely Russian) literature; there is no published
study of this specific three-peptide combination. Selank and Semax have the broader evidence base of
the three. Combination-specific effects are unstudied and should be framed as such.
Human clinical trial data.
No human clinical trial has established administration parameters for the PE-22-28 / Selank / Semax blend; VialTalk does
not provide community-sourced dosing.
Quality & sourcing notes.
A blend COA should confirm each of the three peptides by identity and amount and state the ratio.
Because the three have different physicochemical properties and routes, formulation quality (and
which route the blend is intended for) matters more than for a single peptide.
*Research-use note: This monograph is an educational summary of the published research literature.
This is a vendor blend; its components are research compounds described here for research context
only. Nothing here is medical advice or a usage recommendation.*